BIO101 in Sarcopenia
the world’s most advanced clinical program
the world’s most advanced clinical program
The Medical Need:
Sarcopenia is a disorder characterized by progressive and generalized loss of skeletal muscle mass and strength, reduction of physical performance, and is associated with increased risk of adverse events including disability, poor quality of life, and death.
- Up to 1 in 4 people aged over 60 are affected worldwide
- +178% increased risk of falls
- 3x increased risk of death
- -6 years life expectancy
As of today, there are no approved pharmacological treatments.
Phase 2 Results (SARA-INT):
During the SARA-INT Phase 2 clinical trial, BIO101 demonstrated significant improvement in mobility outcomes, establishing itself as the most advanced drug candidate in Sarcopenia.
- +11% improvement in gait speed (400-meter walk test)
- Clinically meaningful improvement in physical function
